Persistent sexual side effects of finasteride for male pattern hair loss
Irwig, Michael S.; Kolukula, Swapna
The Journal of Sexual Medicine · 8(6):1747-17532011
Abstract (paraphrased)
Interviews with 71 healthy men (21–46 y) who developed sexual side effects on finasteride: 94% low libido, 92% erectile dysfunction/decreased arousal, 69% orgasm problems; average 28 months of use, symptoms persisting on average 40 months after stopping.
Plain-language summary (paraphrased)
The first published case series documenting that finasteride's sexual side effects don't always go away. In 71 young, otherwise healthy men, nearly all reported lasting loss of libido and erectile problems continuing for years after quitting the drug — establishing that persistence, not just occurrence, was the issue.
Why it’s in the corpus
Landmark clinical paper establishing persistent (≥3 month) sexual side effects as a real entity; the clinical foundation of PFS.
Some fields on this page come from the release’s Markdown edition, which carries text the JSON edition omits.
Related records
- Peer-reviewed paper
Persistent sexual side effects of finasteride: could they be permanent?
Irwig, Michael S. · The Journal of Sexual Medicine · 9(11):2927-2932
Prospective reassessment of 54 men (mean 14 months later): 96% still had persistent side effects and 89% met ASEX criteria for sexual dysfunction; duration of finasteride use did not predict recovery.
PFS-0102012PFSCore corpus - Peer-reviewed paper
Post-finasteride syndrome: a surmountable challenge for clinicians
Traish, Abdulmaged M. · Fertility and Sterility · 113(1):21-50
Systematic evaluation of 250+ articles (1989–2019) on finasteride/dutasteride concludes PFS is a real constellation of persistent sexual, neurological, physical and mental effects in a susceptible subset, proposing endocrine disruption plus epigenetic…
PFS-0012020PFSCore corpus - Peer-reviewed paper
The post-finasteride syndrome: clinical manifestation of drug-induced epigenetics due to endocrine disruption
Traish, Abdulmaged M. · Current Sexual Health Reports · 10(3):88-103
Proposes that 5-alpha-reductase inhibitors act as endocrine disruptors, producing drug-induced epigenetic changes in gene expression that explain why symptoms persist after discontinuation.
PFS-0022018PFSCore corpus